Back to Search Start Over

Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment.

Authors :
Berezovsky A
Nuga O
Datta I
Bergman K
Sabedot T
Gurdziel K
Irtenkauf S
Hasselbach L
Meng Y
Mueller C
Petricoin EF 3rd
Brown S
Purandare N
Aras S
Mikkelsen T
Poisson L
Noushmehr H
Ruden D
deCarvalho AC
Source :
PloS one [PLoS One] 2025 Feb 07; Vol. 20 (2), pp. e0315171. Date of Electronic Publication: 2025 Feb 07 (Print Publication: 2025).
Publication Year :
2025

Abstract

Glioblastoma (GBM) tumors exhibit extensive genomic, epigenomic, and transcriptional diversity, with significant intratumoral heterogeneity, complicating standard treatment approaches involving radiation (RT) and the DNA-alkylating agent temozolomide (TMZ). In this study, we employed an integrative multi-omics approach, including targeted proteomics, transcriptomics, genomics, and DNA methylation profiling, to investigate the response of a representative panel of GBM patient-derived cancer stem cells (CSCs) to astrocytic differentiation and RT and TMZ treatments. Differentiated CSC progenies retained the expression of key stemness genes and survival pathways, while activating the BMP-Smad signaling pathway and upregulating extracellular matrix components. This was associated with increased resistance to TMZ, though not to RT, across all models. We identified TP53 status as a critical determinant of transcriptional response to both RT and TMZ, which was also modulated by the differentiation state and treatment modality in wildtype (wt) p53 GBM cells. Both mutant and wt p53 models exhibited significant activation of the DNA-damage associated interferon (IFN) response in CSCs and differentiated cells, implicating this pathway in the GBM response to therapy. We observed that activation of NF-κB was positively correlated with the levels of O-6-methylguanine-DNA methyltransferase (MGMT) protein, a direct DNA repair enzyme leading to TMZ resistance, regardless of MGMT promoter methylation status, further supporting the clinical potential for inhibition of NF-kB signaling in GBM treatment. Our integrative analysis of the impact of GBM cell developmental states, in the context of genomic and molecular diversity of patient-derived models, provides valuable insights for pre-clinical studies aimed at optimizing treatment strategies.<br />Competing Interests: The authors have declared that no competing interests exist.<br /> (Copyright: © 2025 Berezovsky et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Details

Language :
English
ISSN :
1932-6203
Volume :
20
Issue :
2
Database :
MEDLINE
Journal :
PloS one
Publication Type :
Academic Journal
Accession number :
39919036
Full Text :
https://doi.org/10.1371/journal.pone.0315171